The Longevity Show with Dr. Hillary Lin

Hormones are not single data points. Cortisol, progesterone, testosterone, and other hormones change across the day, cycle, sleep, stress, training, and context.In this episode, Dr. Hillary Lin talks with Marina Pavlovic Rivas, cofounder and CEO of Eli Health, about why one annual lab snapshot can miss dynamic physiology — and why more data still needs humility.We cover:saliva testing and what it can/can’t showcortisol curves vs cortisol panicprogesterone/testosterone trackingwellness data vs diagnosticswhy validated at-home testing is hardhow AI in healthcare depends on better inputsEducational only, not medical advice.Chapters:00:00 The Importance of Hormonal Health00:54 The Data Gap in Hormone Health02:43 The Science Behind At-Home Saliva Testing06:17 Understanding Cortisol and Its Impact12:14 Personalizing Cortisol Data vs. Wearable Tracking Limitations15:05 Identifying Overtraining and "Tired but Wired" States18:43 Expanding into Sex Hormones: Progesterone & Testosterone20:40 Tracking Protocols: Finding Trends vs. Creating Noise23:44 The "Anytime, Anywhere" Design Philosophy24:40 Understanding Cortisol and Performance28:31 Factors Influencing Testosterone Levels31:36 Regulatory Boundaries: Wellness vs. Clinical Diagnostics35:18 The Future of Data in Personalized Medicine37:39 The Realities of Deep-Tech Health R&D39:04 Closing Insights for Longevity and Health-Tech FoundersGet Dr. Hillary Lin’s free longevity tips and newsletter: https://www.hillarylinmd.com/subscribeLearn more about Dr. Hillary Lin: https://www.hillarylinmd.com/Explore CareCore: https://carecore.io

What if your workout is making you older? In this episode of The Longevity Show, Dr. Hillary Lin sits down with performance coach Kyle Gonzalez to unpack why longevity training is not just “exercise more.” It is movement throughout the day, recovery, aerobic base, strength, balance, power, glucose control, and building a body that still gives you access to life decades from now.Kyle shares a practical framework for moving more without burning out: why the other 23 hours matter, how to use the 1% rule for exercise, when HIIT helps or backfires, why Zone 2 and walking still matter, how to recover like it is part of training, and what to make of sauna, cold plunge, rucking, barefoot training, HRV, peptides, and more.

There is a drug in clinical trials right now that could permanently fix your cholesterol with a single infusion. Once. That's where we're headed. But there's also a $4 generic that's saved millions of lives — and a twice-a-year injection most patients have never heard of.I'm a Stanford-trained physician. My ApoB was 128. My grandfather died of a stroke. My grandmother died of cardiac arrest. My father is recovering from a heart transplant. In this video, I break down every lipid-lowering option available — without hedging, without liability speak — so you can have an intelligent conversation with your doctor.WHAT YOU'LL LEARN:Why there's no floor for ApoB — the cholesterol-years concept that changes when you start treatmentThe genetics checkpoint: Lp(a), FH, and ancestry factors that change your drug selection entirelyStatins: muscle pain reality, the nocebo effect (SAMSON trial), SLCO1B1 gene, CAC paradox, diabetes signalEzetimibe: the most underused $15/month drug in lipid medicine (IMPROVE-IT data)Bempedoic acid: why it structurally cannot cause muscle toxicity, and what CLEAR Outcomes provedPCSK9 inhibitors: FOURIER + ODYSSEY data, insurance battle, patient assistance programsInclisiran: twice a year, doctor administers — why adherence changes everythingLp(a) pipeline: pelacarsen, olpasiran, muvalaplin — what's coming for the 1 in 4Obicetrapib: oral pill hitting BOTH LDL and Lp(a)Gene therapy: CRISPR + base editing — one injection, once in your lifeLifestyle: honest ceiling assessment, no guiltA tiered protocol framework using ApoB as the treatment targetWhat to actually say to your doctor — 6 specific questionsChapters:05:11 Genetics Checkpoint07:51 Statins16:16 Ezetimibe18:45 Bempedoic Acid25:46 PCSK9 Inhibitors37:20 Inclisiran39:46 Lp(a)44:00 Emerging Therapies + Gene Therapy52:32 Lifestyle56:11 Protocol Framework59:04 What to Say to Your DoctorLINKS:Part 1 — The Disease (Atherosclerosis): https://youtu.be/fX33g1zFZSoPart 2 — The Testing (Why Your Lipid Panel Isn't Enough): https://youtu.be/AtOTY0x3U3IPart 4 — The Genetics: [COMING SOON]Newsletter — The Longevity Letter: https://www.hillarylinmd.com/subscribeFollow me:Instagram: https://instagram.com/hillarylinmdTwitter/X: https://twitter.com/hillarylinmdCareCore (For Clinicians): https://carecore.ioDISCLAIMER: This video is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. Drug dosing, insurance coverage, and clinical guidelines referenced in this video may have changed since filming. I am a physician but I am not your physician.KEY STUDIES REFERENCED:CTT Meta-analysis: 170,000+ patients, 22% event reduction per 1 mmol/L LDL (Lancet 2012)IMPROVE-IT: ezetimibe outcomes, 18,000 patients (NEJM 2015)FOURIER: evolocumab, 27,500 patients, LDL median 30 mg/dL (NEJM 2017)FOURIER-OLE: 8.6-year follow-up, no safety signal at LDL <20 (Circulation 2023)ODYSSEY OUTCOMES: alirocumab, 18,924 post-MI patients (NEJM 2018)SAMSON trial: 90% of statin symptoms also occurred on placebo (NEJM 2020)CLEAR Outcomes: bempedoic acid, 14,000 statin-intolerant patients (NEJM 2023)ORION-10/11: inclisiran, sustained 50-52% LDL reduction (NEJM 2020)VICTORION-2P: inclisiran outcomes trial, ongoingOCEAN(a) Phase 2: olpasiran, >95% Lp(a) reduction (NEJM 2023)Lp(a)HORIZON: pelacarsen outcomes trial, 8,000+ patients, ongoingVERVE-101 heart-1: base editing PCSK9 (Lancet ~2024)NTLA-2001 Phase 1: CRISPR PCSK9 editing (2024)Ference et al.: Mendelian randomization, lifetime LDL (EHJ 2017)#cholesterol #ApoB #statins #PCSK9 #inclisiran #genetherapy #lipids #longevity #heartdisease #preventivemedicine #atherosclerosis #cardiovascular #LDL #lipidplaybook